Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Relapsing C. difficile disease in humans is linked to a pathological imbalance within the intestinal microbiota, termed dysbiosis, which remains poorly understood. We show that mice infected with epidemic C. difficile (genotype 027/BI) develop highly contagious, chronic intestinal disease and persistent dysbiosis characterized by a distinct, simplified microbiota containing opportunistic pathogens and altered metabolite production. Chronic C. difficile 027/BI infection was refractory to vancomycin treatment leading to relapsing disease. In contrast, treatment of C. difficile 027/BI infected mice with feces from healthy mice rapidly restored a diverse, healthy microbiota and resolved C. difficile disease and contagiousness. We used this model to identify a simple mixture of six phylogenetically diverse intestinal bacteria, including novel species, which can re-establish a health-associated microbiota and clear C. difficile 027/BI infection from mice. Thus, targeting a dysbiotic microbiota with a defined mixture of phylogenetically diverse bacteria can trigger major shifts in the microbial community structure that displaces C. difficile and, as a result, resolves disease and contagiousness. Further, we demonstrate a rational approach to harness the therapeutic potential of health-associated microbial communities to treat C. difficile disease and potentially other forms of intestinal dysbiosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Whole genome (maximum likelihood) phylogeny of intestinal bacteria demonstrating the phylogenetic placement of disease-resolving bacteriotherapy bacteria (MixB) and the dominant members of the supershedder microbiota. Maximum likelihood phylogeny produced using FastTree from the concatenated protein sequence of 44 common genes (See methods). Species names marked in green indicate members of the suppressive MixB mixture, names marked in red indicate species that were commonly detected in the feces of supershedding mice, names in black are reference genomes from common intestinal bacteria that were included to provide phylogenetic context to the tree. Taxonomic designations are given at the relevant branch nodes. Adjacent pictures are transmission electron micrographs of sectioned bacterial strains that constitute MixB. Methods for sample processing and imaging have been described [33]. Scale bars are shown below bacteria.](https://figures.cochat.ai/paper-figures/d26cd52a622e48fbb6e5369ce372b754/targeted-restoration-of-the-intestinal-microbiota-with-a-simple-defined-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Decrease in Lachnospiraceae has been associated with severe CDI suggesting a protective role for members of this family51”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Bacterial strains [54, 118, 119] and metabolites [54] associated with protection from C. difficile have now been identified”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
Velvet: Algorithms for de novo short read assembly using de Bruijn graphs
Zerbino, D. R., & Birney, E. (2008) · Genome Research · doi:10.1101/gr.074492.107 · Cited by 9,491
ARB: a software environment for sequence data
Ludwig, W. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh293 · Cited by 6,702
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation
Letunic, I., & Bork, P. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl529 · Cited by 3,299
Identifying bacterial genes and endosymbiont DNA with Glimmer
Delcher, A. L., Bratke, K. A., Powers, E. C., & Salzberg, S. L. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm009 · Cited by 3,134
Colonic Health: Fermentation and Short Chain Fatty Acids
Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00015 · Cited by 2,739
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715 · cited 1×
“Adjusted p-values were calculated using the Benjamini and Hochberg method [57].”
MethodSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501
Cited by
Items 101–200 of 539
Rebollar, E. A., Antwis, R. E., Becker, M. H., Belden, L. K., Bletz, M. C., Brucker, R. M., Harrison, X. A., Hughey, M. C., Kueneman, J. G., Loudon, A. H., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00068 · Cited by 150
“One approach termed Reverse Ecology offers a promising way to use highthroughput genomic data to infer ecological interactions from complex biological systems (Levy and Borenstein, 2012, 2014).”
BackgroundMethodInfluentialPathogenicity and virulence of Clostridioides difficile
Buddle, J. E., & Fagan, R. P. (2022) · Virulence · doi:10.1080/21505594.2022.2150452 · Cited by 169
“Administration of broad-spectrum antimicrobials, either prophylactically or to treat another infection, lead to disruption of the gut microbiota, resulting in a dysbiotic state in which C. difficile thrives [7].”
Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome
Steinway, S. N., Biggs, M. B., Loughran, T. P., Papin, J. A., & Albert, R. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004338 · Cited by 130
“This model-driven approach can be favorably contrasted with the brute-force experimental approach in which successive combinations of microbes are tested until a curative set is found [56].”
ResultLoudon, A. H., Holland, J. A., Umile, T. P., Burzynski, E. A., Minbiole, K. P. C., & Harris, R. N. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00441 · Cited by 136
“Bacterial probiotics with multiple bacterial species have been successful in mouse intestines (Lawley et al., 2012).”
BackgroundGebhart, D., Lok, S., Clare, S., Tomas, M., Stares, M., Scholl, D., Donskey, C. J., Lawley, T. D., & Govoni, G. R. (2015) · mBio · doi:10.1128/mbio.02368-14 · Cited by 127
Self-citationPettit, L. J., Browne, H. P., Yu, L., Smits, W. K., Fagan, R. P., Barquist, L., Martin, M. J., Goulding, D., Duncan, S. H., Flint, H. J., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-160 · Cited by 127
Khanna, S., Montassier, E., Schmidt, B., Patel, R., Knights, D., Pardi, D. S., & Kashyap, P. C. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13750 · Cited by 124
Gut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Microbiomes in respiratory health and disease: An Asia‐Pacific perspective
Chotirmall, S. H., Gellatly, S. L., Budden, K. F., Aogáin, M. M., Shukla, S. D., Wood, D., Hugenholtz, P., Pethe, K., & Hansbro, P. M. (2017) · Respirology · doi:10.1111/resp.12971 · Cited by 127
Deng, H., Yang, S., Zhang, Y., Qian, K., Zhang, Z., Liu, Y., Wang, Y., Bai, Y., Fan, H., Zhao, X., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02976 · Cited by 138
“difficile 027/BI infected mice (Lawley et al., 2012), through helping the host re-establish a health-associated microbiota.”
BackgroundNew opportunities for managing acute and chronic lung infections
Cookson, W., Cox, M. J., & Moffatt, M. F. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.122 · Cited by 128
Emerging insights on intestinal dysbiosis during bacterial infections
Pham, T. A. N., & Lawley, T. D. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.12.002 · Cited by 114
“difficile infection may itself lead to decreased amounts of faecal acetate and butyrate, both in humans and equivalent murine models [25,33].”
BackgroundInfluentialTherapeutic faecal microbiota transplantation: current status and future developments
Borody, T. J., Brandt, L. J., & Paramsothy, S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000027 · Cited by 114
“[5] treated mice with clindamycin and then infected them with C.”
From next-generation sequencing to systematic modeling of the gut microbiome
Ji, B., & Nielsen, J. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00219 · Cited by 114
“Recently, a rational design of microbiota including six phylogenetically diverse intestinal bacteria cleared C. difficile infection in mice and restored the healthy microbiota (Lawley et al., 2012).”
Spore Formation and Toxin Production in Clostridium difficile Biofilms
Semenyuk, E. G., Laning, M. L., Foley, J., Johnston, P. F., Knight, K. L., Gerding, D. N., & Driks, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087757 · Cited by 151
“difficile forms communities in the host in vivo [26,27], Semenyuk, E.”
BackgroundBronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology
Boyton, R. J., & Altmann, D. M. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044344 · Cited by 134
Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns
Pamer, E. G. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.117 · Cited by 122
“Other investigators have assembled small consortia of intestinal bacteria to effectively treat recurrent infection in mice and humans.(39,40) How does FMT cure chronic, recurrent C.”
BackgroundLi, M., Liang, P., Li, Z., Wang, Y., Zhang, G., Gao, H., Wen, S., & Tang, L. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00692 · Cited by 109
“Some researchers have attempted mixed bacterial consortium transplantation (BCT) to re-establish the intestinal ecosystem in animalmodels of digestive and metabolic diseases (Lawley et al., 2012).”
BackgroundLearning from bacterial competition in the host to develop antimicrobials
Raffatellu, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0145-0 · Cited by 121
Pérez-Cobas, A. E., Artacho, A., Ott, S. J., Moya, A., Gosalbes, M. J., & Latorre, A. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00335 · Cited by 105
“In this regard, some studies in mice have shown that Clostridia members, such as Lachnospiraceae, are C. difficile antagonists and restore the microbiota when fed to infected mice (Itoh et al., 1987; Reeves et al., 2011, 2012; Lawley et al., 2012).”
BackgroundStaley, C., Kelly, C. R., Brandt, L. J., Khoruts, A., & Sadowsky, M. J. (2016) · mBio · doi:10.1128/mbio.01965-16 · Cited by 105
“FMT has received increasing attention recently as an effective treatment for rCDI (18–24) with cure rates of (cid:2) 90% (19, 20, 22, 24).”
Rapid transcriptional and metabolic adaptation of intestinal microbes to host immune activation
Becattini, S., Sorbara, M. T., Kim, S. G., Littmann, E. R., Dong, Q., Walsh, G., Wright, R. J., Amoretti, L. A., Fontana, E., Hohl, T. M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.003 · Cited by 109
Jalanka, J., Mattila, E., Jouhten, H., Hartman, J., de Vos, W. M., Arkkila, P., & Satokari, R. (2016) · BMC Medicine · doi:10.1186/s12916-016-0698-z · Cited by 104
“Preliminary studies have been conducted, with evidence from a rCDI mouse model suggesting that a mixture of intestinal bacteria could be used instead of faecal material [22].”
Commensal Koch's postulates: establishing causation in human microbiota research
Neville, B. A., Forster, S. C., & Lawley, T. D. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.10.001 · Cited by 102
“Several excellent examples describe the reintroduction of defined mixtures of commensal strains to prevent or reduce infectious diseases by re-establishing the function of colonisation resistance [8 ,44 ,45,46 ,47 ,48].”
BackgroundBaktash, A., Terveer, E. M., Zwittink, R. D., Hornung, B. V. H., Corver, J., Kuijper, E. J., & Smits, W. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01242 · Cited by 102
The agr Locus Regulates Virulence and Colonization Genes in Clostridium difficile 027
Martin, M. J., Clare, S., Goulding, D., Faulds‐Pain, A., Barquist, L., Browne, H. P., Pettit, L. J., Dougan, G., Lawley, T. D., & Wren, B. W. (2013) · Journal of Bacteriology · doi:10.1128/jb.00473-13 · Cited by 132
Hourigan, S. K., Chen, L. A., Grigoryan, Z., Laroche, G., Weidner, M., Sears, C. L., & Oliva‐Hemker, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13326 · Cited by 101
Stecher, B., Berry, D., & Loy, A. (2013) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12024 · Cited by 115
“Recently, a milestone study by Lawley et al. (2012) identified a simple mixture of phylogenetically diverse intestinal bacteria that mediated clearance of C. difficile infection (‘supershedder’ state) in a mouse model.”
BackgroundInfluentialBrown, J. R.-M., Flemer, B., Joyce, S. A., Zulquernain, A., Sheehan, D., Shanahan, F., & O’Toole, P. W. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0860-5 · Cited by 99
“difficile infection model, [4, 16] the administration of SCFA alone is insufficient to alleviate disease symptoms [16].”
BackgroundThe Use of Defined Microbial Communities To Model Host-Microbe Interactions in the Human Gut
Elzinga, J., John van der, O. O. S. T., de Vos, W. M., & Smidt, H. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00054-18 · Cited by 111
Horrocks, V., King, O. G., Yip, A. Y. G., Marques, I. M., & McDonald, J. A. K. (2023) · Microbiology · doi:10.1099/mic.0.001377 · Cited by 104
Jenior, M. L., Leslie, J. L., Young, V. B., & Schloss, P. D. (2018) · mSphere · doi:10.1128/msphere.00261-18 · Cited by 95
Variations in Virulence and Molecular Biology among Emerging Strains of Clostridium difficile
Hunt, J. J., & Ballard, J. D. (2013) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00017-13 · Cited by 112
“In mice colonized with NAP1/BI/027, the “supershedder” phenotype has been observed in response to antibiotic treatment (189), and this phenotype prolongs transmission to naive mice (190).”
BackgroundEmergent Biosynthetic Capacity in Simple Microbial Communities
Chiu, H.-C., Levy, R., & Borenstein, E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003695 · Cited by 107
“Such transplantation efforts currently utilize complete microbiome transfers from healthy donors or simple synthetic microbiomes constructed from a small collection of carefully handpicked strains [19,21,22].”
BackgroundKlemm, E. J., Wong, V., & Dougan, G. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717162115 · Cited by 104
Landy, J., Walker, A. W., Li, J. V., Al-Hassi, H. O., Ronde, E., English, N. R., Mann, E. R., Bernardo, D., McLaughlin, S. D., Parkhill, J., et al. (2015) · Scientific Reports · doi:10.1038/srep12955 · Cited by 92
Jump, R., Polinkovsky, A., Hurless, K. N., Sitzlar, B. M., Eckart, K. E., Tomas, M. E., Deshpande, A., Nerandzic, M. M., & Donskey, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101267 · Cited by 95
“Swann et al. demonstrated that penicillin and streptomycin-induced alteration of the intestinal microbiota of rats was associated with reduced fecal levels of SCFAs, alanine, lactate, methionine, and Figure 9.”
BackgroundMethodInfluentialColonization Versus Carriage of Clostridium difficile
Donskey, C. J., Kundrapu, S., & Deshpande, A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.001 · Cited by 106
Clostridium Difficile Infection in Older Adults
Jump, R. (2013) · Aging Health · doi:10.2217/ahe.13.37 · Cited by 106
Standardized Preparation for Fecal Microbiota Transplantation in Pigs
Hu, J. P., Chen, L., Tang, Y., Xie, C., Xu, B., Shi, M. Y., Zheng, W., Zhou, S., Wang, X., Liu, L., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01328 · Cited by 100
“Thus, precise manipulation of gut microbiota through probiotics (benign microbes) has currently emerged as a promising therapeutic strategy for gastrointestinal disorders (Foxx-Orenstein and Chey, 2012; Lawley et al., 2012; Buffie et al., 2015; Schieber et al., 2015).”
BackgroundHumanized microbiota mice as a model of recurrent Clostridium difficile disease
Collins, J., Auchtung, J. M., Schaefer, L., Eaton, K. A., & Britton, R. A. (2015) · Microbiome · doi:10.1186/s40168-015-0097-2 · Cited by 98
“treatment with or without re-infection [9, 10] or suppression of initial infection with antibiotics [11] to achieve a relapse-like state.”
BackgroundExploring the influence of the gut microbiota and probiotics on health: a symposium report
Thomas, L. V., Ockhuizen, T., & Suzuki, K. (2014) · British Journal of Nutrition · doi:10.1017/s0007114514001275 · Cited by 89
“difficile infection has also been used to develop a mixture of six phylogenetically diverse intestinal bacteria, which re-established a healthy intestinal microbiota and cleared infection in mice((144)).”
MethodLittmann, E. R., Lee, J.-J., Denny, J. E., Alam, Z., Maslanka, J. R., Zarin, I., Matsuda, R., Carter, R. A., Susac, B., Saffern, M. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20793-x · Cited by 88
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Jarrad, A. M., Karoli, T., Blaskovich, M. A. T., Lyras, D., & Cooper, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5016846 · Cited by 97
Yadegar, A., Pakpour, S., Ibrahim, F. F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A. M., Wong, K., Monaghan, T. M., & Kao, D. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.019 · Cited by 85
Lee, Y. J., Arguello, E. S., Jenq, R. R., Littmann, E., Kim, G. J., Miller, L. C., Ling, L., Figueroa, C., Robilotti, E., Perales, M.-A., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix011 · Cited by 84
Staley, C., Kaiser, T., Vaughn, B. P., Graiziger, C., Hamilton, M. J., Kabage, A. J., Khoruts, A., & Sadowsky, M. J. (2019) · mBio · doi:10.1128/mbio.01586-19 · Cited by 85
“intestinal microbiota, which eventually returned to a healthy state (28).”
BackgroundAnalysis of Bacterial Communities during Clostridium difficile Infection in the Mouse
Semenyuk, E. G., Poroyko, V. A., Johnston, P. F., Jones-Burrage, S. E., Knight, K. L., Gerding, D. N., & Driks, A. (2015) · Infection and Immunity · doi:10.1128/iai.00145-15 · Cited by 92
“For example, in several experimental models, the loss of Lachnospiraceae correlated with increased abundance of Enterobacteriaceae family members (5, 15).”
BackgroundResultInfluentialHost-Microbiota Interactions in the Pathogenesis of Antibiotic-Associated Diseases
Lichtman, J. S., Ferreyra, J. A., Ng, K. M., Smits, S. A., Sonnenburg, J. L., & Elias, J. E. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.009 · Cited by 83
“Work with defined microbial communities suggest that these benefits are derived by changing community structure (Lawley et al., 2012), but the extent to which the host might also mediate a response to the”
BackgroundColonization Resistance of the Gut Microbiota against Clostridium difficile
Pérez-Cobas, A., Moya, A., Gosalbes, M., & Latorre, A. (2015) · Antibiotics · doi:10.3390/antibiotics4030337 · Cited by 83
“Thus, some recent studies focusing on the identification of bacteria involved in resistance colonization against this pathogen in both mice and humans are very promising [95–97,100,115,124].”
BackgroundSmall animal models for the study ofClostridium difficiledisease pathogenesis
Hutton, M. L., Mackin, K. E., Chakravorty, A., & Lyras, D. (2013) · FEMS Microbiology Letters · doi:10.1111/1574-6968.12367 · Cited by 87
“1; Table 1; Theriot et al., 2011; Buffie et al., 2012; Lawley et al., 2012 ).”
BackgroundMethodInfluentialTheriot, C. M., & Young, V. B. (2014) · Gut Microbes · doi:10.4161/gmic.27131 · Cited by 80
“difficile 027/BI strain.(85) The cocktail of six bacteria isolated from the mouse gut consisted of Staphylococcus, Enterococcus, Lactobacillus, Anaerostipes, Bacteroidetes, and Enterorhabdus.”
BackgroundMethodThe role of Clostridium difficile in the paediatric and neonatal gut — a narrative review
Lees, E. A., Miyajima, F., Pirmohamed, M., & Carrol, E. D. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2639-3 · Cited by 91
“These pathogens include: Klebsiella pneumoniae, Proteus 23 mirabilis and Enterococcus faecalis.([22]) Klebsiella pneumoniae and Ruminococcus gnavus 24”
BackgroundMicrobiologic factors affecting Clostridium difficile recurrence
Chilton, C. H., Pickering, D. S., & Freeman, J. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.11.017 · Cited by 85
de Vos, W. M. (2013) · Microbial Biotechnology · doi:10.1111/1751-7915.12047 · Cited by 80
“Best results were obtained with a mixture of six species that included some new mouse isolates (Lawley et al., 2012).”
BackgroundBiofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
Normington, C., Moura, I. B., Bryant, J. A., Ewin, D. J., Clark, E., Kettle, M. J., Harris, H. C., Spittal, W. D., Davis, G. L., Henn, M. R., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00184-w · Cited by 85
Deng, H., Yang, S., Zhang, Y., Qian, K., Zhang, Z., Liu, Y., Wang, Y., Bai, Y., Fan, H., Zhao, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00601 · Cited by 79
Dicksved, J., Ellström, P., Engstrand, L., & Rautelin, H. (2014) · mBio · doi:10.1128/mbio.01212-14 · Cited by 77
Novel perspectives on therapeutic modulation of the gut microbiota
McCarville, J. L., Caminero, A., & Verdu, E. F. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16637819 · Cited by 76
“difficile with healthy stool resolved the infection and they further created a therapeutic synthetic mixture of six strains of bacteria (novel Bacteroidetes species, Lactobacillus reuteri, Enterococcus hirae, novel Anaerostipes species, Straphylococcus warneri and a novel Enterorhabdus species) [Lawley et al. 2012].”
Baines, S. D., & Wilcox, M. H. (2015) · Antibiotics · doi:10.3390/antibiotics4030267 · Cited by 79
“Recent research into selective microbial restoration therapy [128] and feacal microflora transplantation (for review see [129]) has demonstrated positive outcomes in the treatment of”
BackgroundGu, S., Chen, Y., Zhang, X., Lu, H., Lv, T., Shen, P., Lv, L., Zheng, B., Jiang, X., & Li, L. (2015) · Microbes and Infection · doi:10.1016/j.micinf.2015.09.008 · Cited by 83
Ross, C. L., Spinler, J. K., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.006 · Cited by 87
Hudson, L. E., Anderson, S. E., Corbett, A. H., & Lamb, T. J. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00049-16 · Cited by 88
“strated the use of defined bacterial consortia to cure CDI in mice (96) and humans”
BackgroundBella, S. D., Gouliouris, T., & Petrosillo, N. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.01.011 · Cited by 77
New concepts in diagnostics for infectious diarrhea
Platts-Mills, J., Liu, J., & Houpt, E. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.50 · Cited by 70
Microbiota-mediated protection against antibiotic-resistant pathogens
Panwar, R., Sequeira, R. P., & Clarke, T. B. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00129-5 · Cited by 80
Novel Antimicrobials for the Treatment of Clostridium difficile Infection
Petrosillo, N., Granata, G., & Cataldo, M. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00096 · Cited by 79
Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection
Vincent, C., & Manges, A. R. (2015) · Antibiotics · doi:10.3390/antibiotics4030230 · Cited by 82
“have been shown to be effective in preventing recurrent CDI in patients and animal models [83–85].”
BackgroundModulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients
Matijašić, M., Meštrović, T., Perić, M., Paljetak, H. Č., Panek, M., Bender, D. V., Kelečić, D. L., Krznarić, Ž., & Verbanac, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040578 · Cited by 76
Pop, M., Paulson, J. N., Chakraborty, S., Astrovskaya, I., Lindsay, B. R., Li, S., Bravo, H. C., Harro, C. D., Parkhill, J., Walker, A. W., et al. (2016) · BMC Genomics · doi:10.1186/s12864-016-2777-0 · Cited by 81
“Previous studies have attempted to correlate microbiota patterns with prevention or development of gastrointestinal pathogens such as Shigella [43], Clostridium difficile [44] and vancomycin resistant enterococci [45], and have identified candidate species that could be used to enhance defense against these pathogens…”
BackgroundZaatari, M. E., Chang, Y.-M., Zhang, M., Franz, M., Shreiner, A. B., McDermott, A. J., van der Sluijs, K. F., Lutter, R., Grasberger, H., Kamada, N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302913 · Cited by 84
“difficile induces dysbiosis of the intestinal microbiota (7), which is associated with changes in their metabolomic profile (6).”
BackgroundKint, N., Janoir, C., Monot, M., Hoys, S., Soutourina, O., Dupuy, B., & Martin‐Verstraete, I. (2017) · Environmental Microbiology · doi:10.1111/1462-2920.13696 · Cited by 70
Ghimire, S., Roy, C., Wongkuna, S., Antony, L., Fenske, G. J., Maji, A., Keena, M. C., Foley, A., & Scaria, J. (2020) · mSystems · doi:10.1128/msystems.00620-19 · Cited by 79
“Likewise, a mix of six phylogenetically diverse bacteria has been found to alleviate CDI in a mouse model (45).”
BackgroundBassis, C. M., Theriot, C. M., & Young, V. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02262-13 · Cited by 67
Probiotics as a tool for disease mitigation in wildlife: insights from food production and medicine
McKenzie, V. J., Kueneman, J. G., & Harris, R. N. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13617 · Cited by 78
Herzog, M. K.-M., Cazzaniga, M., Peters, A., Shayya, N. W., Beldi, L., Hapfelmeier, S., Heimesaat, M. M., Bereswill, S., Frankel, G. M., Gahan, C. G. M., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172667 · Cited by 81
Muricholic Acids Inhibit Clostridium difficile Spore Germination and Growth
Francis, M. B., Allen, C. A., & Sorg, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073653 · Cited by 67
“difficile strains have been shown to stably colonize mice and enter a ‘contagious’ state, where disease is limited but spore shedding is maintained, while other strains are cleared by the host [13,17].”
BackgroundNovel Indications for Fecal Microbial Transplantation: Update and Review of the Literature
Cohen, N. A., & Maharshak, N. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4535-9 · Cited by 71
Gnotobiotic Rodents: An In Vivo Model for the Study of Microbe–Microbe Interactions
Martín, R., Bermúdez-Humarán, L. G., & Langella, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00409 · Cited by 66
“This hypothesis was further supported by experiments in which the transplantation of healthy fecal microbiota increased host resistance (Barman et al., 2008; Endt et al., 2010; Lawley et al., 2012).”
ResultDoré, J., Simrén, M., Buttle, L., & Guarner, F. (2013) · United European Gastroenterology Journal · doi:10.1177/2050640613502477 · Cited by 65
“A preclinical study has identified a mixture of six phylogenetically diverse intestinal bacteria (Staphylococcus warneri, Enterococcus hirae, Lactobacillus reuteri, and three novel species from Anaerostipes, Bacteroidetes and Enterorhabdus) that re-establish a healthy microbiota and clear CDI from mice.(45) Also, in h…”
BackgroundGreenblum, S., Chiu, H.-C., Levy, R., Carr, R., & Borenstein, E. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.04.001 · Cited by 65
Poquet, I., Saujet, L., Canette, A., Monot, M., Mihajlovic, J., Ghigo, J., Soutourina, O. A., Briandet, R., Martin‐Verstraete, I., & Dupuy, B. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02084 · Cited by 74
“In infected conventional hamsters and mice, rod-shaped bacteria are present as large mats/microcolonies (∼20–30 μm long) at the surface of damaged tissue (Buckley et al., 2011; Lawley et al., 2012).”
BackgroundMa, J., Zhang, J., Li, Q., Shi, Z., Wu, H., Zhang, H., Tang, L., Yi, R., Su, H., & Sun, X. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.02.010 · Cited by 65
Dilip, K. C., Sumner, R., & Lippmann, S. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1662711 · Cited by 72
“difficile colitis, a leading hospital-acquired infection in the United States [8,9].”
BackgroundInfluentialStatus of vaccine research and development for Clostridium difficile
Riley, T. V., Lyras, D., & Douce, G. R. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.052 · Cited by 69
“Such an approach is effective at limiting colonisation in mice [82] but similar combinations for treatment of human disease have still to be evaluated.”
BackgroundSimulations reveal challenges to artificial community selection and possible strategies for success
Xie, L., Yuan, A. E., & Shou, W. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000295 · Cited by 68
“For example, a six-species microbial community, 23 but not any member species alone, cleared relapsing Clostridium difficile infections in mice [1].”
BackgroundNegative interactions determine Clostridioides difficile growth in synthetic human gut communities
Hromada, S. E., Qian, Y., Jacobson, T. B., Clark, R. L., Watson, L., Safdar, N., Amador‐Noguez, D., & Venturelli, O. S. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110355 · Cited by 62
“Multiple synthetic communities that inhibit C. difficile either in vitro or in vivo using murine models have been identified (Tvede & Rask-Madsen, 1989; Lawley et al, 2012; Petrof et al, 2013; Buffie et al, 2014; Ghimire et al, 2020; Pereira et al, 2020).”
InfluentialProbiotics and their Beneficial Health Effects
Zaib, S., Hayat, A., & Khan, I. A. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230608163823 · Cited by 67
McDonald, J. A. K., Fuentes, S., Schroeter, K., Jong, I. H., Khursigara, C. M., de Vos, W. M., & Allen‐Vercoe, E. (2014) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2014.11.007 · Cited by 67
Valdés-Varela, L., Alonso‐Guervós, M., García‐Suárez, O., Gueimonde, M., & Ruas‐Madiedo, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00577 · Cited by 65
Norovirus in healthcare settings
Iturriza‐Gómara, M., & Lopman, B. A. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000094 · Cited by 57
Microbe–microbe interactions during Clostridioides difficile infection
Abbas, A. A., & Zackular, J. P. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.01.016 · Cited by 60
“The protective effect of Lactobacillus given as a monoculture or consortia-based probiotic for CDI has been shown in mice [49,52,53] and in adults and children taking antibiotics [54].”
BackgroundMamo, Y., Woodworth, M. H., Wang, T. L., Dhere, T., & Kraft, C. S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1097 · Cited by 66
“difficile to proliferate in the intestine and produce toxins, leading to acute inflammation and diarrhea [3, 4].”
BackgroundClostridium difficile, the Difficult “Kloster” Fuelled by Antibiotics
Dicks, L. M. T., Mikkelsen, L. S., Brandsborg, E., & Marcotte, H. (2018) · Current Microbiology · doi:10.1007/s00284-018-1543-8 · Cited by 58
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Recent insights into Clostridium difficile pathogenesis
Peniche, A. G., Savidge, T., & Dann, S. M. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000433318.82618.c6 · Cited by 70
Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine
Khoruts, A., Sadowsky, M. J., & Hamilton, M. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.014 · Cited by 58
Lung Microbiota and Its Impact on the Mucosal Immune Phenotype
Wu, B. G., & Segal, L. N. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0005-2016 · Cited by 61
“Observations have noted associations of specific microbes and the gut microbiome in obesity(5–8), coronary artery disease(9–12), Clostridium difficile colitis(13, 14), type 2 diabetes(15, 16), and inflammatory bowel disease(4, 17, 18).”
Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria
Hwang, I. Y., Koh, E., Kim, H. R., Yew, W. S., & Chang, M. W. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.002 · Cited by 57
Roychowdhury, S., Cadnum, J., Glueck, B., Obrenovich, M., Donskey, C., & Cresci, G. A. M. (2018) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1053 · Cited by 54
Metadata
- Authors
- Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., Deakin, L. J., Pickard, D. J., Duncan, S. H., Flint, H. J., Clark, T. G., Parkhill, J., & Dougan, G.
- Affiliations
- Wellcome Sanger Institute (GB)
- University of Aberdeen (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Corresponding author
- Lawley, Trevor D.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-25
- Volume
- 8
- Issue
- 10
- Pages
- e1002995
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3486913
- OpenAlex
- W2171605634
- Cited by
- 540
- References
- 73
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 19 · 2023: 20 · 2022: 24 · 2021: 33 · 2020: 21 · 2019: 37 · 2018: 47 · 2017: 42 · 2016: 71 · 2015: 65 · 2014: 73 · 2013: 61 · 2012: 6
- FWCI
- 45.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Wellcome Trust (076964, 098051)
- Medical Research Council (098051, 93614)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, dysbiosis, bacterial therapy, fecal microbiota transplantation, transmissibility, opportunistic pathogens, microbial metabolites, mouse model
- MeSH terms
- Animals, Enterocolitis, Pseudomembranous, Feces, Female, Intestines, Mice, Inbred C3H, Mice, Inbred C57BL, Molecular Sequence Data, Recurrence, Vancomycin, Clostridioides difficile, Probiotics, Drug Resistance, Bacterial, Mice, Microbial Interactions, Microbial Consortia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.